Aptevo Therapeutics
APVO
9 hedge funds and large institutions have $224K invested in Aptevo Therapeutics in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 9 → 9 (0)
0.5% less ownership
Funds ownership: 4.55% → 4.05% (-0.5%)
2% less capital invested
Capital invested by funds: $230K → $224K (-$5.31K)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$9.15K |
| 2 |
Barclays
London,
United Kingdom
|
+$149 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$13.1K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
-$12.1K |
APVO Hedge Fund Activity: Q2 2026 in Review
9 of the 8,343 institutional investors tracked by Wall St. Rank reported a position in Aptevo Therapeutics (APVO) for Q2 2026, worth a combined $224K — down 2.3% from $230K a quarter earlier.
Buyers outnumbered sellers: 1 fund opened new APVO positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 2 trimmed.
The largest buyer was GSA Capital Partners, adding an estimated $9.15K. The largest seller was UBS Group, cutting an estimated $13.1K.
- 9 institutional investors held Aptevo Therapeutics (APVO) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $224K of Aptevo Therapeutics stock for Q2 2026, down 2.3% quarter-over-quarter.
- 1 fund opened new Aptevo Therapeutics positions in Q2 2026 and 0 closed out, a net change of +1 holder.
- The largest Aptevo Therapeutics buyer in Q2 2026 was GSA Capital Partners, an estimated $9.15K added.
- The largest Aptevo Therapeutics seller in Q2 2026 was UBS Group, an estimated $13.1K sold.
Based on aggregated 13F filings for Q2 2026.